Lowest Price Guaranteed
Slides
165
Last Updated
July 2026
View Count
19151
SECTION I: REPORT OVERVIEW
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
SECTION II: QUALITATIVE INSIGHTS
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Introduction to RSV Vaccines
6.2. Structure and Mechanism of RSV
6.3. Key Historical Events Related to RSV Vaccines
6.4. Types of RSV Vaccines
6.4.1. Nucleic Acid Based Vaccines
6.4.2. Protein Based Vaccines
6.4.3. Recombinant Vector Based Vaccines
6.4.4. Live Attenuated Vaccines
6.5. Benefits of RSV Vaccination
6.6. Challenges Associated with Development of RSV Vaccines
6.7. Future Perspectives
SECTION III: MARKET OVERVIEW
7. MARKET LANDSCAPE
7.1. RSV Vaccines: Overall Market Landscape
7.1.1. Analysis by Stage of Development
7.1.2. Analysis by Route of Administration
7.1.3. Analysis by Type of Vaccine
7.1.4. Analysis by Type of Protein Targeted
7.1.5. Analysis by Type of Immunization
7.1.6. Analysis by Target Patient Population
7.1.7. Analysis by Year of Establishment
7.1.8. Analysis by Company Size
7.1.9. Analysis by Location of Headquarters
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Assumptions and Key Parameters
8.2. Methodology
8.3. RSV Vaccines: Product Competitiveness Analysis
8.3.1. RSV Vaccines Developed by Players Based in North America
8.3.2. RSV Vaccines Developed by Players Based in Europe
8.3.3. RSV Vaccines Developed by Players Based in Asia-Pacific and Rest of the World
SECTION IV: COMPANY PROFILES
9. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN NORTH AMERICA
9.1. Icosavax (A Company of AstraZeneca)
9.1.1. Company Details
9.1.2. Product Portfolio
9.1.3. Recent Developments and Future Outlook
9.2. Moderna
9.2.1. Company Details
9.2.2. Product Portfolio
9.2.3. Financial Details, FY 2021 onwards (USD Million)
9.2.4. Recent Developments and Future Outlook
9.3. Pfizer
9.3.1. Company Details
9.3.2. Product Portfolio
9.3.3. Financial Details, FY 2021 onwards (USD Million)
9.3.4. Recent Developments and Future Outlook
10. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN EUROPE
10.1. GlaxoSmithKline
10.1.1. Company Details
10.1.2. Product Portfolio
10.1.3. Financial Details, FY 2021 onwards (EUR Million)
10.1.4. Recent Developments and Future Outlook
10.2. Sanofi
10.2.1. Company Details
10.2.2. Product Portfolio
10.2.3. Financial Details, FY 2021 onwards (EUR Million)
10.2.4. Recent Developments and Future Outlook
11. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN ASIA-PACIFIC
11.1. Beijing Advaccine Biotechnology
11.1.1. Company Details
11.1.2. Product Portfolio
SECTION V: MARKET TRENDS
12. CLINICAL TRIALS ANALYSIS
12.1. Scope and Methodology
12.2. RSV Vaccines: Clinical Trial Analysis
12.2.1. Analysis by Trial Registration Year, Since 2015
12.2.2. Analysis by Trial Status
12.2.3. Analysis of Enrolled Patient Population by Trial Registration Year, Since 2015
12.2.4. Analysis by Trial Registration Year and Trial Status, Since 2015
12.2.5. Analysis by Trial Phase
12.2.6. Analysis of Enrolled Patient Population by Trial Phase
12.2.7. Analysis by Study Design
12.2.8. Analysis by Type of Sponsor / Collaborator
12.2.9. Analysis by Gender
12.2.10. Analysis by Target Patient Population
12.2.11. Leading Players: Analysis by Number of Registered Trials
12.2.12. Analysis by Geography
12.2.13. Analysis by Trial Status and Geography
12.2.14. Analysis of Enrolled Patient Population by Trial Status and Geography
13. PATENT ANALYSIS
13.1. Scope and Methodology
13.2. RSV Vaccines: Patent Analysis
13.2.1. Analysis by Patent Publication Year, Since 2020
13.2.2. Analysis by Type of Patent
13.2.3. Analysis by Type of Patent and Publication Year, Since 2020
13.2.4. Analysis by Patent Application Year, Since 2008
13.2.5. Analysis by Patent Age
13.2.6. Analysis by Type of Applicant
13.2.7. Analysis by Patent Jurisdiction
13.2.8. Analysis by CPC Symbols
13.2.9. Leading Industry Players: Analysis by Number of Patents
13.2.10. Leading Non-Industry Players: Analysis by Number of Patents
13.2.11. Leading Inventors: Analysis by Number of Patents
13.3. Patent Benchmarking Analysis
13.3.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
13.3.2. Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
13.4. Patent Valuation
13.5. Leading Patents by Number of Citations
14. FDA APPROVAL STRATEGIES
14.1. Chapter Overview
14.2. Methodology
14.3. Key Parameters
14.4. General Reasons for Failure of Trials Focused on RSV vaccines
14.5. Benchmarking Analysis: Distribution of Key Strategies by Vaccines
SECTION VI: MARKET OPPORTUNITY ANALYSIS
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Market Drivers
15.2. Market Restraints
15.3. Market Opportunities
15.4. Market Challenges
16. GLOBAL RSV VACCINE MARKET
16.1. Key Assumptions and Methodology
16.2. Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
16.2.1. Multivariate Scenario Analysis
16.2.1.1. Conservative Scenario
16.2.1.2. Optimistic Scenario
16.3. Key Market Segmentations
17. RSV VACCINE MARKET, BY TYPE OF VACCINE
17.1. Key Assumptions and Methodology
17.2. RSV Vaccine Market: Distribution by Type of Vaccine
17.2.1. RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
17.2.2. RSV Vaccine Market for Live Attenuated Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
17.2.3. RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
17.3. Data Triangulation and Validation
18. RSV VACCINE MARKET, BY ROUTE OF ADMINISTRATION
18.1. Key Assumptions and Methodology
18.2. RSV Vaccine Market: Distribution by Route of Administration
18.2.1. RSV Vaccine Market for Intramuscular, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
18.2.2. RSV Vaccine Market for Other Routes, Historical Trends (Since2023) and Forecasted Estimates Till 2040) (USD Million)
18.3. Data Triangulation and Validation
19. RSV VACCINE MARKET, BY TARGET PATIENT POPULATION
19.1. Key Assumptions and Methodology
19.2. RSV Vaccine Market: Distribution by Target Patient Population
19.2.1. RSV Vaccine Market for Elderly Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
19.2.2. RSV Vaccine Market for Infants / Children, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
19.2.3. RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
19.3. Data Triangulation and Validation
20. RSV VACCINE MARKET, BY DISTRIBUTION CHANNEL
20.1. Key Assumptions and Methodology
20.2. RSV Vaccine Market: Distribution by Distribution Channel
20.2.1. RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
20.2.2. RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
20.2.3. RSV Vaccine Market for Others, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
20.3. Data Triangulation and Validation
21. RSV VACCINE MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Key Assumptions and Methodology
21.2. RSV Vaccine Market: Distribution by Key Geographical Regions
21.2.1. RSV Vaccine Market in North America, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
21.2.2. RSV Vaccine Market in Europe, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
21.3. Market Movement Analysis
21.4. Penetration-Growth (P-G) Matrix
21.5. Data Triangulation and Validation
22. MARKET CONCENTRATION ANALYSIS: DISTRIBUTION BY LEADING PLAYERS
22.1. Key Assumptions and Methodology
22.2. RSV Vaccine Market: Leading RSV Vaccines Developers
22.3. Data Triangulation and Validation
SECTION VII: MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHICAL REGIONS**
23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
23.1. RSV Vaccine Market in North America: Distribution by Type of Vaccine
23.1.1. RSV Vaccine Market in North America for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.1.2. RSV Vaccine Market in North America for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.1.3. RSV Vaccine Market in North America for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.2. RSV Vaccine Market in North America: Distribution by Route of Administration
23.2.1. RSV Vaccine Market in North America for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.2.2. RSV Vaccine Market in North America for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3. RSV Vaccine Market in North America: Distribution by Target Patient Population
23.3.1. RSV Vaccine Market in North America for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.2. RSV Vaccine Market in North America for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.3.3. RSV Vaccine Market in North America for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4. RSV Vaccine Market in North America: Distribution by Distribution Channel
23.4.1. RSV Vaccine Market in North America for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.2. RSV Vaccine Market in North America for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
23.4.3. RSV Vaccine Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24. MARKET OPPORTUNITY ANALYSIS: EUROPE
24.1. RSV Vaccine Market in Europe: Distribution by Type of Vaccine
24.1.1. RSV Vaccine Market in Europe for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1.2. RSV Vaccine Market in Europe for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.1.3. RSV Vaccine Market in Europe for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.2. RSV Vaccine Market in Europe: Distribution by Route of Administration
24.2.1. RSV Vaccine Market in Europe for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.2.2. RSV Vaccine Market in Europe for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.3. RSV Vaccine Market in Europe: Distribution by Target Patient Population
24.3.1. RSV Vaccine Market in Europe for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.3.2. RSV Vaccine Market in Europe for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.3.3. RSV Vaccine Market in Europe for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.4. RSV Vaccine Market in Europe: Distribution by Distribution Channel
24.4.1. RSV Vaccine Market in Europe for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.4.2. RSV Vaccine Market in Europe for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
24.4.3. RSV Vaccine Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
**Detailed information on Section VII is available in the Excel Data Packs shared along with the report**
SECTION VIII: OTHER EXCLUSIVE INSIGHTS
25. CONCLUSION
26. EXECUTIVE INSIGHTS
SECTION IX: APPENDIX
27. TABULATED DATA
28. LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control Framework
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Structure of RSV
Figure 6.2 Key Historical Events Related to RSV Vaccines
Figure 7.1 RSV Vaccines: Distribution by Stage of Development
Figure 7.2 RSV Vaccines: Distribution by Route of Administration
Figure 7.3 RSV Vaccines: Distribution by Type of Vaccine
Figure 7.4 RSV Vaccines: Distribution by Type of Protein Targeted
Figure 7.5 RSV Vaccines: Distribution by Type of Immunization
Figure 7.6 RSV Vaccines: Distribution by Target Patient Population
Figure 7.7 RSV Vaccine Developers: Distribution by Year of Establishment
Figure 7.8 RSV Vaccine Developers: Distribution by Company Size
Figure 7.9 RSV Vaccine Developers: Distribution by Location of Headquarters
Figure 8.1 Product Competitiveness Analysis: RSV Vaccines Developed by Players Based in North America (with product competitiveness score of more than 3.4)
Figure 8.2 Product Competitiveness Analysis: RSV Vaccines Developed by Players Based in North America (with product competitiveness score of less than or equal to 3.4)
Figure 8.3 Product Competitiveness Analysis: RSV Vaccines Developed by Players Based in Europe
Figure 8.4 Product Competitiveness Analysis: RSV Vaccines Developed by Players Based in Asia-Pacific and Rest of the World
Figure 9.1 Moderna: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (USD Million)
Figure 9.2 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (USD Million)
Figure 10.1 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
Figure 10.2 Sanofi: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2015
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2015
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2015
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 12.7 Clinical Trial Analysis: Distribution by Study Design
Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.9 Clinical Trial Analysis: Distribution by Gender
Figure 12.10 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 12.11 Leading Players: Distribution by Number of Registered Trials
Figure 12.12 Clinical Trial Analysis: Distribution by Geography
Figure 12.13 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 12.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 13.1 Patent Analysis: Distribution by Patent Publication Year, Since 2020
Figure 13.2 Patent Analysis: Distribution by Type of Patent
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Figure 13.4 Patent Analysis: Distribution by Patent Application Year, Since 2008
Figure 13.5 Patent Analysis: Distribution by Patent Age
Figure 13.6 Cumulative Year-wise Distribution by Type of Applicant
Figure 13.7 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.8 Patent Analysis: Distribution by CPC Symbols
Figure 13.9 Leading Industry Players: Distribution by Number of Patents
Figure 13.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 13.11 Leading Inventors: Distribution by Number of Patents
Figure 13.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.13 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.14 RSV Vaccines: Patent Valuation
Figure 14.1 FDA Approval Strategies: Distribution of Key Strategies by Vaccines
Figure 16.1 Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 16.2 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Conservative Scenario (USD Million)
Figure 16.3 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Optimistic Scenario (USD Million)
Figure 17.1 RSV Vaccine Market: Distribution by Type of Vaccine
Figure 17.2 RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 17.3 RSV Vaccine Market for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 17.4 RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 18.1 RSV Vaccine Market: Distribution by Route of Administration
Figure 18.2 RSV Vaccine Market for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 18.3 RSV Vaccine Market for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 19.1 RSV Vaccine Market: Distribution by Target Patient Population
Figure 19.2 RSV Vaccine Market for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 19.3 RSV Vaccine Market for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 19.4 RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 20.1 RSV Vaccine Market: Distribution by Distribution channel
Figure 20.2 RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 20.3 RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 20.4 RSV Vaccine Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 21.1 RSV Vaccine Market: Distribution by Key Geographical Regions
Figure 21.2 RSV Vaccine Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 21.3 RSV Vaccine Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Figure 21.4 Market Movement Analysis: Key Geographical Regions
Figure 21.5 Penetration Growth Matrix: Key Geographical Regions
Figure 22.1 RSV Vaccine Market: Distribution by Leading Players
Figure 23.1 Conclusion: Market Landscape
Figure 23.2 Conclusion: Clinical Trial Analysis
Figure 23.3 Conclusion: Patent Analysis
Figure 23.4 Conclusion: Market Sizing and Opportunity Analysis
Table 7.1 RSV Vaccines: Information on Developer, Stage of Development, Route of Administration and Type of Vaccine
Table 7.2 RSV Vaccines: Information on Type of Protein Targeted, Type of Immunization and Target Patient Population
Table 7.3 RSV Vaccines: List of Developers
Table 9.1 Icosavax (A Company of AstraZeneca): Product Portfolio
Table 9.2 Moderna: Product Portfolio
Table 9.3 Pfizer: Product Portfolio
Table 10.1 GlaxoSmithKline: Product Portfolio
Table 10.2 Sanofi: Product Portfolio
Table 11.1 Beijing Advaccine Biotechnology: Product Portfolio
Table 13.1 RSV Vaccine Market: List of Published Patents
Table 23.1 RSV Vaccine Market in North America: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 23.2 RSV Vaccine Market in North America: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 23.3 RSV Vaccine Market in North America: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 23.4 RSV Vaccine Market in North America: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 24.1 RSV Vaccine Market in Europe: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 24.2 RSV Vaccine Market in Europe: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 24.3 RSV Vaccine Market in Europe: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 24.4 RSV Vaccine Market in Europe: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
**Detailed information on Tables 23.1-24.4 is available in the Excel Data Packs shared along with the report
Table 27.1 RSV Vaccines: Distribution by Stage of Development
Table 27.2 RSV Vaccines: Distribution by Route of Administration
Table 27.3 RSV Vaccines: Distribution by Type of Vaccine
Table 27.4 RSV Vaccines: Distribution by Type of Protein Targeted
Table 27.5 RSV Vaccines: Distribution by Type of Immunization
Table 27.6 RSV Vaccines: Distribution by Target Patient Population
Table 27.7 RSV Vaccine Developers: Distribution by Year of Establishment
Table 27.8 RSV Vaccine Developers: Distribution by Company Size
Table 27.9 RSV Vaccine Developers: Distribution by Location of Headquarters
Table 27.10 Moderna: Consolidated Financial Details, FY 2021 onwards (USD Million)
Table 27.11 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (USD Million)
Table 27.12 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
Table 27.13 Sanofi: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
Table 27.14 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2015
Table 27.15 Clinical Trial Analysis: Distribution by Trial Status
Table 27.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2015
Table 27.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2015
Table 27.18 Clinical Trial Analysis: Distribution by Trial Phase
Table 27.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 27.20 Clinical Trial Analysis: Distribution by Study Design
Table 27.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 27.22 Clinical Trial Analysis: Distribution by Gender
Table 27.23 Clinical Trial Analysis: Distribution by Target Patient Population
Table 27.24 Leading Players: Distribution by Number of Registered Trial
Table 27.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 27.26 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 27.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 27.28 Patent Analysis: Distribution by Patent Publication Year, Since 2020
Table 27.29 Patent Analysis: Distribution by Type of Patent
Table 27.30 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Table 27.31 Patent Analysis: Distribution by Patent Application Year, Since 2008
Table 27.32 Patent Analysis: Distribution by Patent Age
Table 27.33 Cumulative Year-wise Distribution by Type of Applicant
Table 27.34 Patent Analysis: Distribution by Patent Jurisdiction
Table 27.35 Leading Industry Players: Distribution by Number of Patents
Table 27.36 Leading Non-Industry Players: Distribution by Number of Patents
Table 27.37 Leading Inventors: Distribution by Number of Patents
Table 27.38 RSV Vaccines: Patent Valuation
Table 27.39 Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
Table 27.40 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Conservative Scenario (USD Million)
Table 27.41 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Optimistic Scenario (USD Million)
Table 27.42 RSV Vaccine Market: Distribution by Type of Vaccine
Table 27.43 RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.44 RSV Vaccine Market for Live Attenuated / Chimeric Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.45 RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.46 RSV Vaccine Market: Distribution by Route of Administration
Table 27.47 RSV Vaccine Market for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.48 RSV Vaccine Market for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.49 RSV Vaccine Market: Distribution by Target Patient Population
Table 27.50 RSV Vaccine Market for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.51 RSV Vaccine Market for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.52 RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.53 RSV Vaccine Market: Distribution by Distribution channel
Table 27.54 RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.55 RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.56 RSV Vaccine Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.57 RSV Vaccine Market: Distribution by Key Geographical Regions
Table 27.58 RSV Vaccine Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.59 RSV Vaccine Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
Table 27.60 Market Movement Analysis: Key Geographical Regions
Table 27.61 Penetration Growth Matrix: Key Geographical Regions
Table 27.62 RSV Vaccine Market: Distribution by Leading Players
Please reach out to our team for more details.